Address: 2, ul. Chermyanskaya, 127282 Moscow,Russia
Tel: + 7 (495) 730-78-28
Web: http://www.protek-group.ru/eng
Protek Group is one of one of the lagest pharmaceutical company in Russia*. The Group has diversified business interests and is active in all major segments of the pharmaceutical industry such as manufacture of medicinal products, wholesaling and retailing of pharmaceuticals, beauty and health products. The Group employs more than 12 thousand people.
The Group is vertically integrated, which enables it to set up a complete product supply chain from Production to Wholesale to Retail sales. The Group’s key assets: CV Protek, a national distributor of pharmaceuticals, beauty and health products; Sotex, a manufacturer of medical products; and Rigla pharmacy chain. In 2002, as part of the Group’s restructuring, OAO Protek was set up as the Group’s parent company to consolidate the equity interests (shares) in its subsidiaries and associates.
CV Protek is a major distributor of pharmaceuticals, beauty and health products in Russia. It has been active in Russia’s pharmaceutical market since 1990. Based on it’s 2010 performance, CV Protek takes first place in overall ranking of pharmaceutical distributors**. The company supplies medicines to all 83 constituent territories of the RF; its total warehouse space, according to 2010 figures, is near 159,000 sq.m.
Rigla pharmacy chain comes second in the ranking of major pharmacy chains in Russia in terms of sales**. The chain boasts 655*** pharmacies in 26 regions of Russia and Ukraine.
The Production segment is based on Sotex company. The company’s manufacturing facility, located in the Sergiyev-Posad district of the Moscow region, makes ampoule injection solutions of liquid INPN generics, patented-content medicines and its own-brand medicines. The facility is one of the most advanced high-tech pharmaceutical manufacturers in Russia.
Protek Group embraces state-of-the-art standards in financial management. Its core elements are as follows: corporate financial reporting in compliance with the International Accounting Standards (IAS), international audit, sound financial policies, and Oracle E-Business Suite-based enterprise resource planning in segments.
The Group’s business practices aim to improve the competitiveness and resilience of the Group’s business as a whole, and to maximize the market cap of each company in its segment.
The Group is active in a socially significant sector and is committed to socially responsible business practices, fully honouring its obligations to its partners, staff and society. The Group provides sponsorship and charitable donations for cultural, historical and research projects, as well as humanitarian assistance.
Protek Group’s mission: Our mission is to care for human beauty and health. We put a premium on the economic, social and ethical values of society, honour our commitments to the public, partners and the government, thus setting business standards.
* In terms of sales
**Source: DSM Group
*** Company data on 31.06.2011
Vertically integrated pharmaceutical comany operating in production, distribution/wholesale, and retail
Can you please introduce our readers to ProTek Medical? ProTek Medical was founded in 1995 to serve a growing healthcare market by partnering closely with our customers in precision injection…
In spring of 2010, Protek became the first Russian wholesaler to enter the public stock market, raising $400Mn in the biggest Russian IPO since 2007. You offered the IPO directly…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
